CAMBRIDGE, Mass. (November 22, 2019) – InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the closing of its previously announced public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. The gross proceeds from this offering are $840,000, before deducting the fees and estimated offering expenses payable by InVivo Therapeutics. The offering closed on November 22, 2019.
H.C. Wainwright & Co. acted as exclusive placement agent for the offering.
A registration statement on Form S-3 (File No. 333-234353) relating to the shares of common stock offered in the offering was filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on November 14, 2019. The offering was made only by means of a prospectus supplement and accompanying base prospectus, which are part of the effective registration statement. A final prospectus supplement related to the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, via e-mail at firstname.lastname@example.org or via telephone at (646) 975-6996.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp., or the Company, is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA.